SpectrumX Healthcare
- Focused on protecting people's ability to interact socially with SpectriPODs
- Providing high quality testing solutions
- Aiming to reduce infection pathways of all viral and bacterial infections
SpectrumX Medical
- Providing ground-breaking nebulised treatments for COVID-19 patients
- Exploring efficacy of treatments against other infections
- Developing alternative therapies for mass consumer use
SpectrumX
Direct
- Promoting the multitude of benefits of HOCL in beauty sector
- D2C skincare ranges removing harsh, skin-damaging effects of alcohol-based sanitisers
- Ecommerce with mass consumer focus
FURTHER INFORMATION
What is Hypochlorous Acid?
SpectrumX are leaders in proprietary formulations of HOCL (Hypochlorous Acid). Through their partnership with Spectrum Antimicrobials, California, USA they hold various licenses for the use of their unique formulations.
First discovered in 1834, it has taken the technological advancements of SpectrumX to, for the first time, produce a stable, efficacious formulation that performs in real world conditions.
“HOCL has been well researched, published and later cleared by FDA in different therapeutic areas including reduction of topical inflammation and topical pain as well as disinfection of food and food preparation areas. However, none of the above mentioned products have been able to provide stability at lower concentrations for safe use of the product on people. Spectrum Antimicrobials unique and patented formulations provide rapid disinfection in the presence of soil and other organic matter, at concentrations of 0.032% where other HOCL based products have been shown to certainly fail in stability and performance.”
Dr. Jerry Stonemetz
Medical Director, Johns Hopkins University Hospital
What Should I Do Next?
We have passed your details to their Investor Relations team. Please expect contact from them and check your email for an introductory email.
Visit Their Website
UPDATE
This Raise Has Proved Popular With Our Investors
This raise has proved very popular with initial investors and is filled faster than anticipated. Make sure you don’t miss out on this future biotech giant.
We have passed your details to their Investor Relations team. Please expect contact from them and check your email for an introductory email.
Not sure where to start?
We’d recommend speaking to one of our consultants. To qualify,
you must be a high net worth individual or a sophisticated investor.
Quickly confirm your eligible and we’ll set things up.